FindTrial
Sign In

Study on the Benefits of PRGF (Plasma Rich in Growth Factors) for Knee Joint Pain

Evaluation of Functional Outcomes of Plasma Rich in Growth Factors (PRGF) in Knee Osteoarthritis: An Unicentric, open Label Double-Blinded Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/096920
Enrollment
72
Registered
2025-11-04
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M170- Bilateral primary osteoarthritis of knee

Interventions

Intervention1: Characterization of PRGF and PRP: Characterization of PRGF and PRP will be performed with apparently healthy donor blood samples (10) by incubating whole blood samples with an externa

Sponsors

Dr Ravi Kerur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: **Inclusion Criteria:** 1. Male and female adults aged 18 years or older 2. Radiological diagnosis of multicompartmental knee osteoarthritis 3. Joint pain of 60 mm or more according to the Visual Analog Scale (range 0–100 mm) 4. Radiological severity classified as Grade I to III on the Kellgren–Lawrence scale 5. Body Mass Index (BMI) less than 30 kg/m² 6. Availability for examination during the follow-up period

Exclusion criteria

Exclusion criteria: Body Mass Index more or equal to 30 Diagnosis of polyarticular disease • Severe mechanical deformity (bidiaphyseal varus, 4; valgus, 16) • Previous Knee surgery • Hyaluronic acid or corticosteroid injections within the last 3 months. • Diagnosis of systemic autoimmune rheumatoid disease (connective tissue disease and systemic necrotizing vasculitis) • Uncontrolled diabetes mellitus (glycosylated hemoglobin more than 7 percent ) • Blood disorders (thrombopathy, thrombocytopenia, anemia with hemoglobin level less than 9) • Ongoing immunosuppressive and or dicumarinic therapy • Use of non-steroidal anti-inflammatory drugs within 15 days before inclusion in the study

Design outcomes

Primary

MeasureTime frame
To Evaluate functional outcomes of Plasma Rich in Growth Factors (PRGF) and Platelet-Rich Plasma (PRP) in osteoarthritis of Knee.Timepoint: baseline day 14, 1 month, 3 months, 6 months, and 12 months post injection.—

Secondary

MeasureTime frame
To evaluate the effects of Plasma Rich in Growth Factors (PRGF) & Platelet-Rich Plasma (PRP) on pain, cartilage repair, patient satisfaction & safety.Timepoint: baseline day 14, 1 month, 3 months, 6 months, & 12 months post injection.—

Countries

India

Contacts

Public ContactDr Rajesh Mane

KLE University of Higher Sciences and Research

drrajeshmane@gmail.com9844131062

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026